GAITHERSBURG, Md.--(BUSINESS WIRE)--GenVec, Inc. (Nasdaq:GNVC) announced today that it has executed the first option period from the previously announced agreement with the U.S. Department of Homeland Security (DHS) that will provide $5.6 million over the next 12 months to support the development of vaccines for the prevention of foot-and-mouth disease (FMD).
